0001209191-21-056057.txt : 20210914
0001209191-21-056057.hdr.sgml : 20210914
20210914192946
ACCESSION NUMBER: 0001209191-21-056057
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210914
FILED AS OF DATE: 20210914
DATE AS OF CHANGE: 20210914
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Burgess Paul D.
CENTRAL INDEX KEY: 0001744627
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38550
FILM NUMBER: 211253769
MAIL ADDRESS:
STREET 1: C/O TRANSLATE BIO, INC.
STREET 2: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Translate Bio, Inc.
CENTRAL INDEX KEY: 0001693415
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 611807780
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-945-7361
MAIL ADDRESS:
STREET 1: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: RaNA Therapeutics, Inc.
DATE OF NAME CHANGE: 20161228
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-09-14
0
0001693415
Translate Bio, Inc.
TBIO
0001744627
Burgess Paul D.
C/O TRANSLATE BIO, INC.
29 HARTWELL AVE
LEXINGTON
MA
02421
0
1
0
1
Chief Operating Officer, CLO
Secretary
Common Stock
2021-09-14
4
S
0
71833
38.00
D
0
D
Stock Option (right to buy)
7.39
2021-09-14
4
S
0
219652
0.00
D
2027-12-21
Common Stock
219652
0
D
Stock Option (right to buy)
8.34
2021-09-14
4
S
0
69953
0.00
D
2028-03-06
Common Stock
69953
0
D
Stock Option (right to buy)
7.95
2021-09-14
4
S
0
150000
0.00
D
2029-03-07
Common Stock
150000
0
D
Stock Option (right to buy)
7.66
2021-09-14
4
S
0
150000
0.00
D
2030-03-02
Common Stock
150000
0
D
Stock Option (right to buy)
23.82
2021-09-14
4
S
0
90000
0.00
D
2031-03-08
Common Stock
90000
0
D
As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021.
Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
This option was granted on December 22, 2017. The shares underlying the option became fully vested on March 9, 2021.
This option was granted on March 7, 2018. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 7, 2019 and the remainder vesting in equal monthly installments through March 7, 2022.
This option was granted on March 8, 2019. This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023.
This option was granted on March 3, 2020. This option will vest as to 25% of the shares on December 11, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through December 11, 2023.
This option was granted on March 9, 2021. This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares though March 9, 2025.
/s/ Paul D. Burgess
2021-09-14